Tumor Microenvironment Responsive Nanogel for the Combinatorial Antitumor Effect of Chemotherapy and Immunotherapy

Song, Qingle; Yin, Yijia; Shang, Lihuan; Wang, Tingting; Zhang, Dan; Kong, Miao; Zhao, Yongdan; He, Yangzhou; Tan, Songwei; Guo, Yuanyuan; Zhang, Zhiping

doi:10.1021/acs.nanolett.7b03186

Cited by 221 publications

(163 citation statements)

References 59 publications

Supporting

Mentioning

155

Contrasting

Unclassified

Order By: Relevance

“…The RBC‐coated nanoparticles targeted mannose receptors on dendritic cells, followed by the intracellular cleavage of redox‐sensitive peptide conjugates, thus triggering potent dendritic cell‐mediated CD8 + T cell responses and inhibiting the growth of melanoma. Afterward, the same group synthesized a pH responsive RBC‐coated nanogel loaded with IL‐2 and paclitaxel for combination therapy . Low‐dose paclitaxel induced immunogenic cancer cell death, thus reconstructing immune surveillance in tumor site by dendritic cells; IL‐2 then provided survival signals to effector cells to obtain a potent synergistic antitumor effect.…”

Section: Nanoscale Materials For Immunotherapymentioning

confidence: 99%

Materials for Immunotherapy

et al. 2019

View full text Add to dashboard Cite

Breakthroughs in materials engineering have accelerated the progress of immunotherapy in preclinical studies. The interplay of chemistry and materials has resulted in improved loading, targeting, and release of immunomodulatory agents. An overview of the materials that are used to enable or improve the success of immunotherapies in preclinical studies is presented, from immunosuppressive to proinflammatory strategies, with particular emphasis on technologies poised for clinical translation. The materials are organized based on their characteristic length scale, whereby the enabling feature of each technology is organized by the structure of that material. For example, the mechanisms by which i) nanoscale materials can improve targeting and infiltration of immunomodulatory payloads into tissues and cells, ii) microscale materials can facilitate cell‐mediated transport and serve as artificial antigen‐presenting cells, and iii) macroscale materials can form the basis of artificial microenvironments to promote cell infiltration and reprogramming are discussed. As a step toward establishing a set of design rules for future immunotherapies, materials that intrinsically activate or suppress the immune system are reviewed. Finally, a brief outlook on the trajectory of these systems and how they may be improved to address unsolved challenges in cancer, infectious diseases, and autoimmunity is presented.

show abstract

Section: Nanoscale Materials For Immunotherapymentioning

confidence: 99%

Materials for Immunotherapy

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The localised tumour microenvironment is characterised by extreme metabolic processing and rapid, uncontrolled replication and therefore possesses singular features that can be exploited for site-specific targeting [62,63]. A typical tumour undergoes rapid and progressive angiogenesis to form abnormal vasculature for the increased supply of nutrients and oxygen [64].…”

Section: Discussionmentioning

confidence: 99%

Sterically Stabilised Polymeric Mesoporous Silica Nanoparticles Improve Doxorubicin Efficiency: Tailored Cancer Therapy

Moodley

Singh

2020

Molecules

View full text Add to dashboard Cite

The fruition, commercialisation and clinical application combining nano-engineering, nanomedicine and material science for utilisation in drug delivery is becoming a reality. The successful integration of nanomaterial in nanotherapeutics requires their critical development to ensure physiological and biological compatibility. Mesoporous silica nanoparticles (MSNs) are attractive nanocarriers due to their biodegradable, biocompatible, and relative malleable porous frameworks that can be functionalized for enhanced targeting and delivery in a variety of disease models. The optimal formulation of an MSN with polyethylene glycol (2% and 5%) and chitosan was undertaken, to produce sterically stabilized, hydrophilic MSNs, capable of efficient loading and delivery of the hydrophobic anti-neoplastic drug, doxorubicin (DOX). The pH-sensitive release kinetics of DOX, together with the anticancer, apoptosis and cell-cycle activities of DOX-loaded MSNs in selected cancer cell lines were evaluated. MSNs of 36-60 nm in size, with a pore diameter of 9.8 nm, and a cumulative surface area of 710.36 m 2 /g were produced. The 2% pegylated MSN formulation (PCMSN) had the highest DOX loading capacity (0.98 mg dox /mg msn ), and a sustained release profile over 72 h. Pegylated-drug nanoconjugates were effective at a concentration range between 20-50 µg/mL, inducing apoptosis in cancer cells, and affirming their potential as effective drug delivery vehicles.Molecules 2020, 25, 742 2 of 22 MSNs possess a large active surface area which can be selectively polymerised or functionalised for stimuli-responsive purposes [11], tunable pore size and large pore volumes for the loading and controlled release of the cargo, and have shown favourable tolerance levels both in vitro and in vivo [12][13][14].MSNs are being extensively researched as theranostic devices for diseases, especially for cancer therapy [15]. Conventional cancer treatment options such as surgery, radiotherapy and chemotherapy [16], have not been fully effective, resulting in snowballing recurrence rates and depression in the quality of life [17,18]. Unpleasant side-effects are often linked to the anti-neoplastic drugs used, which act by inhibiting cellular mechanisms of DNA replication that are up-regulated in cancer cells. These cytostatic or cytotoxic compounds usually have low bioavailability and are thus administered at high dosages or for prolonged dosing intervals, leading to systemic side effects at non-specific sites [19,20].Doxorubicin (DOX) remains one of the most efficient anthracycline drugs available and is used in the treatment of diverse cancers, including breast, cervical, bone, gastric and leukaemia [21][22][23]. Despite its popularity, its low solubility [24][25][26], coupled with increased dosing frequencies [27][28][29] has resulted in many associated side effects, including cardiotoxicity [30][31][32], myelosuppression [33,34], induced vomiting with nausea [35,36], and alopecia [18,37]. Critical evaluation of these detrimental side-effects that become more...

show abstract

“…There are several examples of employing biomimetic nanotechnology to induce ICD for anticancer therapy. RBC membranes have been used to coat nanomaterials to improve their circulation and to protect encapsulated cargoes . In the case of certain chemotherapeutics, delivery by cell membrane–coated nanoparticles gives them a greater chance of localizing to the tumor site, where they can be released to trigger ICD.…”

Section: Biomimetic Anticancer Nanovaccinesmentioning

confidence: 99%

Biomimetic Nanotechnology toward Personalized Vaccines

et al. 2019

View full text Add to dashboard Cite

While traditional approaches for disease management in the era of modern medicine have saved countless lives and enhanced patient well‐being, it is clear that there is significant room to improve upon the current status quo. For infectious diseases, the steady rise of antibiotic resistance has resulted in super pathogens that do not respond to most approved drugs. In the field of cancer treatment, the idea of a cure‐all silver bullet has long been abandoned. As a result of the challenges facing current treatment and prevention paradigms in the clinic, there is an increasing push for personalized therapeutics, where plans for medical care are established on a patient‐by‐patient basis. Along these lines, vaccines, both against bacteria and tumors, are a clinical modality that could benefit significantly from personalization. Effective vaccination strategies could help to address many challenging disease conditions, but current vaccines are limited by factors such as a lack of potency and antigenic breadth. Recently, researchers have turned toward the use of biomimetic nanotechnology as a means of addressing these hurdles. Recent progress in the development of biomimetic nanovaccines for antibacterial and anticancer applications is discussed, with an emphasis on their potential for personalized medicine.

show abstract

Tumor Microenvironment Responsive Nanogel for the Combinatorial Antitumor Effect of Chemotherapy and Immunotherapy

Cited by 221 publications

References 59 publications

Materials for Immunotherapy

Materials for Immunotherapy

Sterically Stabilised Polymeric Mesoporous Silica Nanoparticles Improve Doxorubicin Efficiency: Tailored Cancer Therapy

Biomimetic Nanotechnology toward Personalized Vaccines

Contact Info

Product

Resources

About